Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
0.106
+0.003 (2.42%)
At close: Apr 28, 2026, 4:00 PM EDT
0.100
-0.006 (-5.66%)
After-hours: Apr 28, 2026, 6:40 PM EDT
Propanc Biopharma Employees
As of June 30, 2025, Propanc Biopharma had 2 total employees, including 1 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$33,500,093
Market Cap
2.22M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Calidi Biotherapeutics | 29 |
| BiomX | 20 |
| Silexion Therapeutics | 14 |
| Biodexa Pharmaceuticals | 11 |
| Decoy Therapeutics | 11 |
| Adial Pharmaceuticals | 5 |
PPCB News
- 5 weeks ago - Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain - GlobeNewsWire
- 6 weeks ago - Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy - GlobeNewsWire
- 7 weeks ago - Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study - GlobeNewsWire
- 2 months ago - Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models - GlobeNewsWire
- 2 months ago - Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results - GlobeNewsWire
- 2 months ago - Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market - GlobeNewsWire
- 3 months ago - Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations - GlobeNewsWire
- 3 months ago - Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - GlobeNewsWire